Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel

Pharmaceutical Research

Volumn 17, Issue 2, 2000, Pages 175-182

  Constantinides, Panayiotis P ^a   Lambert, Karel J ^a   Tustian, Alex K ^a   Schneider, Brian ^a   Lalji, Salima ^a   Ma, Wenwen ^a   Wentzel, Bryan ^a   Kessler, Dean ^a   Worah, Dilip ^a   Quay, Steven C ^a  

^a Sonus Pharmaceuticals   (United States)

Author keywords

Emulsions; Filter sterization; Paclitaxel; Particle size; Stability

Indexed keywords

PACLITAXEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG TOLERABILITY; EMULSION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MAXIMUM ALLOWABLE CONCENTRATION; MELANOMA; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EMULSIONS; FEMALE; FILTRATION; HUMANS; MELANOMA; MICE; MICE, INBRED STRAINS; PACLITAXEL; PARTICLE SIZE; SERUM ALBUMIN; SKIN NEOPLASMS; SOLUBILITY; STERILIZATION; SURVIVAL ANALYSIS; VITAMIN E;

EID: 0034063079     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007565230130     Document Type: Article

References (34)

1. 1. E. K. Rowinsky and Donehower, R. C. Paclitaxel (Taxol). N. Engl. J. Med. 332:1004-1014 (1995).
2. 2. S. B. Horwitz. Mechanism of action of taxol. Trends in Pharma. Sci. (TIPS) 13:134-135 (1992).
3. 3. R. M. Straubinger. Biopharmaceutics of paclitaxel (taxol): formulation, activity and pharmacokinetics, in Taxol®: Science and Applications (M. Suffness ed.). CRC Press, Boca Raton, pp. 237-258 (1996).
4. 4. A. Sparreboom, J. Van Asperen, U. Meyer, A. H. Schinkel, J. W. Smit, D. K. F. Meijer, P. Borst, W. J. Nooijen, J. H. Beijen, and O. Van Tellingen. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by p-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA 94:2031-2035 (1997).
5. 5. W. Lorenz, H. J. Reimann, A. Schmal, H. Schult, S. Lang, C. Ohmann, D. Weber, B. Kapp, L. Luben, and A. Doenicke. Histamine release in dogs by Cremophor EL and its derivatives: oxyethylated oleic acid is the most effective constituent. Agents Actions 7:63-67 (1977).
6. 6. D. Dye and J. Watkins. Suspected anaphylactic reaction to Cremophor EL. Br. Med. J. 280:1353 (1980).
7. 7. B. D. Tarr, T. G. Sambandan, and S. H. Yalkowsky. A new parenteral emulsion for the administration of taxol. Pharm. Res. 4:162-165 (1987).
8. 8. R. J. Kaufman, T J. Richard, and R. W. Fuhrhop. Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same. U.S. Patent 5,616,330, April 1, 1997.
9. 9. B. Lundberg. A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). J. Pharm. Pharmacol. 49:16-21 (1997).
10. 10. P. Simamora, R-M. Dannenfelser, S. E. Tabibi, and S. H. Yalkowsky. Emulsion formulations for intravenous administration of paclitaxel. PDA J. Pharm. Sci. Technol. 52:170-172 (1998).
11. 11. P. P. Constantinides, K. Lambert, A. K. Tustian, W. Ma, B. Schneider, S. Lalji, B. Wentzel, D. Kessler, D. Worah, and S. C. Quay. Reduced toxicity and improved efficacy of paclitaxel incorporated in oil-in-water emulsions. Pharm Sci. 1:S-100 (1998).
12. 12. A. Sharma, E. Mayhew, and R. M. Straubinger. Antitumour effect of taxol containing liposomes in a taxol-resistant murine tumor model. Cancer Res. 53:5877-5881 (1993).
13. 13. A. Sharma and R.M. Straubinger. Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm. Res. 11:889-896 (1994).
14. 14. H. Alkan-Onyuksel, S. Ramakrishnan, H.-B. Chai, and J. M. Pezzuto. A mixed micellar formulation suitable for the parenteral administration of taxol. Pharm. Res. 2:206-212 (1994).
15. 15. U. S. Sharma, S. V. Balasubramanian and R. M. Straubinger. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. J. Pharm. Sci. 84:1223-1230 (1995).
16. 16. Y. M. Wang, H. Sato, and I. Horikoshi. In vitro and in vivo evaluation of taxol release from poly(lactic-co-glycolic acid) microspheres containing isopropyl myristate and degradation of the microspheres. J. Contr. Rel. 49:157-166 (1997).
17. 17. C. Li, D-F., Yu, T. Inoue, D. J. Yang, L. Milas, N. R. Hunter, E. E. Kim, and S. Wallace. Synthesis and evaluation of water-soluble polyethylene glycol paclitaxel conjugate as paclitaxel prodrug. Anticancer Drugs 7:642-648 (1996).
18. 18. C. Li, D-F., Yu, R. A. Newman, C. Fernando, L. C. Stephens, N. Hunter, L. Milas, and S. Wallace. Complete regression of well-established tumors using a novel water-soluble poly (L-glutamic acid)-paclitaxel conjugate. Cancer Res. 58:2404-2409 (1998).
19. 19. R. G. Waldeigh, R. S. Redman, M. L. Graham, S. H. Krasnow, A. Anderson, and M. H. Cohen. Vitamin E in the treatment of chemotherapy-induced mucositis. Am. J. Med. 92:481-484 (1992).
20. 20. A. Geetha, R. Sankar, T. Marar, and C. S. Shyamala-Devi. α-Tocopherol reduces doxorubicin-induced toxicity in rats-histological and biochemical evidences. Ind. J. Physiol. Pharmac. 34: 94-100 (1990).
21. 21. S. D. Harvey, J. A. Campbell, R. G. Kesley, and N. C. Vance. Separation of paclitaxel from related taxanes in Taxus brevifolia extracts by isocratic elution reverse-phase microcolumn high-performance liquid chromatography. J. Chromatogr. 582:273-278 (1991).
22. 22. N. S. Santos Magalhaes, G. Cave, M. Seiller, and S. Benita. The stability and in vitro release kinetics of a clofibride emulsion. Int. J. Pharm. 76:225-237 (1991).
23. 23. W. Rose. Preclinical Antitumor Activity of Taxanes, in Taxol®: Science and Applications (M. Suffness ed.), CRC Press, Boca Raton, pp. 237-258 (1996).
24. 24. J. Plowman, D. J. Dykes, M. Hollingshead, L. Simpson-Herren, and M. C. Alley. Human tumor xenograft models in NCI development, in Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials and Approval (B. A. Teicher ed.), Humana Press, Totowa, New Jersey, pp. 101-125 (1997).
25. 25. L. C. Collins-Gold, R. T. Lyons, and L. C. Bartholow. Parenteral emulsions for drug delivery. Adv. Drug Del. Rev. 5:189-208 (1990).
26. 26. D. M. Lidgate, T. Trattner, R. M. Shultz, and R. Maskiewicz. Sterile filtration of a parenteral emulsion. Pharm. Res. 9:860-863 (1992).
27. 27. A. Kurihara, Y. Shibayama, A. Mizota, A. Yasuno, M. Ikeda, K. Sasagawa, T. Kobayashi, and M. Hisaoka. Enhanced tumor delivery and antitumor activity of palmitoyl rhizoxin using stable lipid emulsions in mice. Pharm. Res. 13:11305-11320 (1996).
28. 28. C. Washington. Drug release and interfacial structure in emulsions, in Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs (R. H. Muller, S. Benita and B. Bohm, eds), MedPharm Scientific Publishers, Stuttgart, Germany, pp. 101-117 (1998).
29. 29. F. Liu and D. Liu. Long-circulating emulsions (oil-in-water) as carriers for lipophilic drugs. Pharm. Res. 12:1060-1064 (1995).
30. 30. M. C. Bissery, D. Guenard, F. Gueritte-Voegelein, and F. Lavelle. Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), the marketed formulation of docetaxel, Cancer Res. 51:4845-4852 (1991).
31. 31. P. C. Gokhale, J.T. Newsome, A. Dritschilo, U. Kasid and A. Rahman. Toxicity, histopathologic and pharmacokinetic evaluation of liposome-encapsulated paclitaxel and taxol in mice and rabbits. Proc. Amer. Assoc. Cancer Res. 40:#2759 (1999).
32. 32. I. Ahmad, W. Perkins, G. R. Masters, J. Nguyen, X. Li, J. J. Schupsky, S. Ali, A. S. Janoff, and Mayhew, E. Therapeutic efficacy of a novel polyethyleneglycol (PEG)-lipid formulation of 2' [alpha]-bromo-hexedecanoyl paclitaxel (BrC16HT) against human tumor xenografts in SCID mice. Proc. Amer. Assoc. Cancer Res. 40:#3849 (1999).
33. 33. W. C. Rose. Preclinical antitumor activity of taxanes, in Taxol® Science and Applications (M. Suffness ed.) CRC Press, Boca Raton, pp. 209-235 (1996).
34. 34. D. D. Lasic, F. J. Martin, A. Gabizon, S. K. Huang, and D. Papahadjopoulos. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim. Biophys. Acta 1070:187-192 (1991).